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2009 and to propose measures to improve the quality of the surveillance system
in the Republic of Korea.
Methods
The epidemiological data for rubella and CRS cases reported to the Korea Centers
for Disease Control and Prevention from 2001 to 2009 were retrospectively
reviewed, and insurance reimbursement data from the Korea National Health
Insurance Review Agency were collected for comparison.
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Objectives
The aim of this study was to review the epidemiologic data of rubella and
congenital rubella syndrome (CRS) supplied by surveillance systems from 2001 to
Thenumberof yearly reported rubella cases to theKoreaCenters forDiseaseControl
and Prevention from 2001 to 2009 was 128, 24, 8, 24, 15, 12, 35, 30, and 36,
respectively. The occurrence of rubella shifted to a slightly higher age group during
the 9-year period, i.e. from 0e9 years to 10e19 years. Among the 309 reported
rubella cases, three were confirmed cases of CRS. In addition, according to data
sourced from Health Insurance Review Agency, 24, 19, 19, 9, and 5 CRS cases were
reported for medical insurance reimbursement from 2005 to 2009, respectively.
Conclusion
According to available surveillance data, the reported cases of rubella and CRS
were not high, but a more detailed surveillance with emphasis on susceptible
women of childbearing age is necessary for better monitoring and control of
rubella and CRS in the Republic of Korea.r Disease Control and Prevention, 194, Tongil-ro, Eunpyeong-gu, Seoul 122-701, Korea.
ibuted under the terms of the Creative Commons Attribution Non-Commercial License
y-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in
is properly cited.
ol and Prevention. Published by Elsevier. All rights reserved.
24 Y.J. Choe et al1. Introduction government to implement a Five-Year Measles Elimi-Rubella, a mild febrile viral exanthematous disease, is
an important public health concern because of its asso-
ciation with congenital rubella syndrome (CRS), which
can result in miscarriage, stillbirth, and multiple birth
defects including deafness, blindness, heart disease, and
mental retardation.1 Although rubella itself is a well-
controlled disease that is preventable through vaccina-
tion in some nations,2,3 widespread epidemics of the
disease and significant morbidity and mortality from
CRS still exist in other parts of the world.4,5
Since its introduction in the 1960s, vaccination
against rubella was a significant factor in the prevention
of rubella and CRS. Two different strategies have been
used to control rubella and CRS: in the United States, all
infants from 12 to 15 months of age are vaccinated,6
whereas in the United Kingdom, susceptible women of
childbearing age are vaccinated.7 Both strategies were
partially successful, which prompted the strategies to be
revised to include vaccination of both populations (i.e.
12e15-month-old infants and susceptible women of
childbearing age) by means of a universal dual vacci-
nation strategy.8 On the other hand, a comprehensive
two-dose measles-mumps-rubella (MMR) vaccination
program along with national surveillance and high
vaccination coverage, as implemented in Finland, has
led to success in the elimination of rubella and CRS in
that country.9
In the Republic of Korea, the vaccine for rubella was
first introduced in a monovalent form in 1978 and
became standard in 1982 when the MMR combination
vaccine was introduced. The MMR vaccine was rec-
ommended for all infants aged 15 months, but the actual
vaccine coverage rate was not known. In 1997, a second
dose of MMR was added to the schedule for children
aged 4e6 years, in addition to the dose received at
12e15 months. However, because of insufficient poli-
cies to promote the second-dose coverage, the two-dose
MMR vaccine coverage rate was low at 39% in 200110
and thus resulted in a large nationwide outbreak of
measles in 2000e2001.
Before 2000, when the Prevention of Contagious
Diseases Act was implemented, the reported case of
rubella in the Republic of Korea was rare, and only
a minor outbreak in Seoul in 1963 was recorded.11 In the
mid-1990s, a rubella outbreak among the adolescent
population led to a change in policy from universal
vaccination of infants to selective vaccination of all
adolescent girls in tenth grade of high school.12 Before
the institution of vaccination to adolescent girls, a cost-
benefit analysis study has revealed that both rubella
vaccination policies were found to be cost-effective, but
vaccination to adolescent girls were more effective than
vaccination to infants of both sexes.12 However, a large
outbreak of measles in 2000 and 2001 prompted thenation Program, which involved a nationwide measles-
rubella catch-up vaccination program targeting the
population aged from 8 to 16 years.10 This campaign
eliminated the selective vaccination program that tar-
geted adolescent females, and a universal vaccination of
all infants from 12 to 15 months of age and children
from 4 to 6 years of age was implemented.13
Meanwhile, a surveillance system for rubella and
CRS in conjunction with nine other vaccine-preventable
diseases (i.e. diphtheria, pertussis, tetanus, measles,
mumps, polio, hepatitis B, Japanese encephalitis, and
chickenpox) has been implemented since 2001, and all
cases of suspected rubella are requested to be reported
immediately to the Korea Centers for Disease Control
and Prevention (KCDC).
The World Health Organization (WHO) has recom-
mended that countries that implement the rubella
vaccine should conduct surveillance for rubella and CRS
as a part of the measles surveillance system.14 The
minimum requirements for the surveillance system
include monthly routine reporting of suspected CRS
cases with zero reporting, monthly routine reporting of
suspected rubella cases, investigation of all febrile rash
illnesses in pregnant women, and testing for rubella-
specific immunoglobulin M (IgM) antibodies in any
suspected rubella outbreaks.15 Recently, the Republic of
Korea has experienced a series of measles outbreaks,
which prompted attention to improve the surveillance
system for measles. In conjunction with measles, the
need to re-evaluate the surveillance for monitoring
rubella and CRS has been raised. The aim of this study
was to review the reported cases of rubella and CRS
supplied by the surveillance system from 2001 to 2009
and to propose measures to improve the quality of the
surveillance system in the Republic of Korea.
2. Methods
The epidemiological data for rubella and CRS cases
under the Prevention of Contagious Diseases Act16 were
reported to the KCDC from 2001 to 2009. A suspected
rubella case was defined as any patient presenting
clinical symptoms of rubella; a confirmed rubella case
was defined as any patient presenting clinical symptoms
of rubella with laboratory confirmation [i.e. a positive
blood test for rubella-specific IgM, 4-fold increase in
immunoglobulin G (IgG) in paired serum samples, or
virus isolation]. A suspected CRS case was defined as
any infant with clinical symptoms of CRS; a confirmed
CRS case was defined as any infant in whom clinical
symptoms of CRS were presented with laboratory
confirmation (i.e. the presence of positive rubella-
specific IgM or isolation of virus).17 For each case,
a thorough investigation by an epidemic intelligence
service officer was provided, including recording the
Table 1 Annual reported cases of rubella, by age
Years 0e9 10e19 20e29 30e39 40e49 50 Total cases
2001 58 59 5 5 0 1 128
2002 10 9 3 1 0 1 24
2003 4 2 1 1 0 0 8
2004 11 2 1 1 0 0 15
2005 7 1 0 2 2 0 12
2006 7 5 5 1 0 0 18
2007 10 8 10 6 1 0 35
2008 13 10 4 3 0 0 30
2009 13 14 6 2 1 0 36
Surveillance and control of rubella in Korea 25date of disease onset and patient sex, age, symptoms,
vaccination status, and recent travel history.
The Korean Health Insurance Review Agency
(HIRA) collects detailed data from Korean citizens
regarding medical care and expenses as well as the
amount to be paid as insurance. The agency consolidates
available nationwide statistical and medical records. We
obtained data regarding CRS cases in patients aged less
that 1 year from 2005 to 2009 from the HIRA.
In the Republic of Korea, the 2001 Five-Year
Measles Elimination Program established a laboratory
surveillance that mandates all specimens submitted to
the KCDC for measles testing to be routinely tested for
rubella IgM and IgG.10 Any cases of suspected measles
identified as rubella after laboratory testing were trans-
ferred to the rubella surveillance system.
3. Results
Before the implementation of the Prevention of Conta-
gious Diseases Act in 2000,16 which mandated that all
health care personnel report suspected cases of rubella
and CRS to the government, reported cases of rubellaFigure 1 Annual reported cases of rubella repoand CRS were scarce. In 2001, after continued outbreaks
of measles, the Five-Year Measles Elimination Program
introduced a two-dose MMR vaccination for children
aged 12e15 months and 4e6 years.10 As a result, the
reported case of rubella was declined from 128 cases in
2001 down to a record low of only eight cases in 2003.
For the years 2002, 2003, 2004, 2005, and 2006, the
number of cases of rubella reported was 24, 24, 15, 12,
and 18, respectively. The reported cases were slightly
higher in 2007, 2008, and 2009, when 35, 30, and 36
cases were reported, respectively.
The highest reported cases were observed in the age
groups of 0e9 and 10e19 years, which were 58 and 59 in
2001, respectively (Table 1). These reported cases were
decreased to 10 and 9 in 2002 and to four and two in 2003,
respectively, after the implementation of the two-dose
MMR vaccination policy. In 2004, the highest reported
cases were detected in the age group representing below
10 years (11/15, 73.3%), which decreased to 58.3% in
2005, 38.9% in 2006, 28.6% in 2007, 43.3% in 2008, and
36.1% in 2009 (Figure 1). Conversely, the reported cases
between the ages 10 years and 19 years increased from
8.3% in 2005 to 27.8% in 2006, 22.9% in 2007, 33.3% inrted in the Republic of Korea, 2001e2009.
Figure 2 Percentages of age-specific reported cases of rubella.
26 Y.J. Choe et al2008, and 38.9% in 2009 (Figure 2). From 2001 to 2009,
no documented outbreak of rubella was reported.
The reported case of rubella among women aged
15e44 years was 6 in 2006, 16 in 2007, 3 in 2008, and 5
in 2009. The reported case of CRS was one in 2008 and
two in 2009. Among the three confirmed CRS cases, the
first case was of a male, who had cataract and a kidney
anomaly in infancy and whose mother had gestational
diabetes mellitus. The second case was of a prematurely
born female with cataract and chorioretinitis. The third
case was of a male, who was born prematurely at 29
weeks of gestational age with a birth weight of 1000 g,
with ear anomalies and a ventricular septal defect
(Table 2). The latter two cases were admitted to the
neonatal intensive care unit, and outcomes were not
described.
According to the data from HIRA, the number of
CRS cases reported for reimbursement from 2005 to
2009 was 24, 19, 19, 9, and 5, respectively (Table 3).Table 2 Reported cases of rubella among women aged 15e44
because of rubella infection in pregnant women, and t
Years Reported rubella among women
aged 15e44 yr
2006 6
2007 16
2008 3
2009 5
CRSZ congenital rubella syndrome.4. Discussion
The reported cases of rubella has declined from 128
cases in 2001 to 36 cases in 2009, probably because of
the comprehensively increased vaccine coverage rate
from 84% of first dose of MMR in 199918 to nearly 99%
in 2009.19 However, the actual trend of rubella inci-
dence remains unknown because of insufficient infor-
mation reported before 2001. In addition, it is possible
that the reported rubella cases in 2001 could be over-
estimated because of large outbreak of measles, which
led to actively capture under-diagnosed rubella cases
and more reporting of suspected cases. Because of
limited data before year 2000, the present study does not
provide evidence that the Five-Year Measles Elimina-
tion Program, which resulted in mass vaccination of
more than 5 million susceptible populations and
a mandated second dose of MMR vaccination to chil-
dren aged 4e6 years,10 has reduced the actual incidenceyears, number of reported therapeutic abortions performed
he reported cases of congenital rubella syndrome
Number of therapeutic abortions Reported CRS
1 0
5 0
0 1
2 2
Table 3 Reported cases of congenital rubella syndrome
from data retrieved from the Korean Health
Insurance Review Agency, 2005e2009
Years 2005 2006 2007 2008 2009
Male 12 6 10 4 2
Female 12 13 9 5 3
Total 24 19 19 9 5
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Korea.
Before the present study, there were only few
reported cases of CRS in the Republic of Korea.20
Despite a reduction of 71.9% of rubella cases between
2001 and 2009, three cases of confirmed CRS occurred
in 2008 and 2009. The reported CRS cases were
confirmed by clinical criteria as well as positive labo-
ratory results. However, information regarding the case
patients and their mothers, including birth weight,
gestational age, and prenatal courses, was not complete.
Follow-up outcome status was not recorded. The present
study suggests a lack of validity of the rubella surveil-
lance system currently implemented in the Republic of
Korea.
Rubella elimination plans are established in most
countries in the measles elimination phase. In 2000, the
WHO recommended joint surveillance for suspected
measles and rubella as febrile exanthematous illness
surveillance.21 There is special emphasis regarding
focused surveillance for infants less than 1 year of age
with heart disease, cataracts, or deafness because such
illness may provide an opportunity to accumulate
information on the CRS disease burden.15 Currently, the
precise incidence of congenital heart disease22,23
(0.89%e1.27%), infantile cataract,24 and congenital
deafness25 has not yet been postulated at the nationwide
level in the Republic of Korea. In addition to nationwide
epidemiology studies of these three conditions, detailed
communications between infection specialists, neona-
tologists, ophthalmologists, cardiologists, and hearing
specialists will be required to conduct an active
surveillance of CRS.
Currently, the RA 27/3 strain of rubella is the only
vaccine strain available in the Republic of Korea.26 An
immunogenicity analysis of the vaccine revealed the
seroconversion rate of the antibody to be nearly 100%;27
thus the vaccine itself is not a mere problem in the
control of rubella and CRS in the Republic of Korea. In
2007, it was reported that the estimated MMR vaccine
coverage rate in the Republic of Korea was 93.2% for
the first dose, but there was low second dose vaccine
coverage: 24.2%, 42.3%, and 59.0% for children aged 4,
5, and 6 years, respectively.28 The considerably higher
proportion of children who remain unvaccinated despite
the mandatory two-dose MMR vaccine established since2001 remains a concern. In addition, the level of
susceptible childbearing age women should be vigilantly
monitored and the surveillance system needs to account
for such monitoring. According to a recent study con-
ducted by the Korea Food and Drug Administration in
2009 (unpublished data), the seropositivity rate of
rubella IgG was 100.0% among females aged 2e24
years, 90.0% in 25- to 26-year-old women, and 97.8% in
27- to 30-year-old women. Women with negative
rubella IgG are at risk of rubella infection and at higher
risk for CRS when exposed to the virus during
pregnancy.
Recently, the increasing portion of immigration of
women of childbearing age from developed countries
may pose a higher risk of rubella virus transmission
and CRS. Therefore, identifying all cases of rubella
that occur in the Republic of Korea as well as moni-
toring women of childbearing age and foreign-born
persons will be essential in improving surveillance for
CRS.
As stated by the WHO, the primary purpose of
a rubella vaccination is to prevent the occurrence of
CRS.15 The surveillance system to detect and control
rubella should reflect this objective. The discrepancy of
reported cases of CRS among data from the KCDC and
HIRA may suggest that the CRS surveillance system
currently operating in the Republic of Korea is
inadequate.
In conclusion, the present study questions the validity
and ultimately the utility of the current rubella and CRS
monitoring system in place in the Republic of Korea. A
more detailed surveillance with greater emphasis on
susceptible women of childbearing age may provide
a more reliable system for monitoring and controlling
both rubella and CRS in the Republic of Korea.References
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